ESPR - Earnings call transcript Q4 2020 | Esperion Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by, and welcome. [Operator Instructions]. Please be advised that today's conference call may be recorded. I would now like to hand the conference call over to Ben Church, Investor Relations and Corporate Communications at Esperion. Please go ahead, sir.

Benjamin Church

operator. you, Thank welcome XXXX and Fourth and Quarter Good Results to and Year Financial Call. Company Full afternoon, Esperion's Update Conference Church, for responsible here and and Ben Communications at Investor Corporate Esperion. I'm Relations I'm Officer; Officer. today's on and Mayleben, Chief Operating are With Sheldon Chief me Chief Financial call Koenig, Bartram, President Tim and Executive Rick Officer; the today under the safe I want the that covered callers Litigation information discussed Act. provisions is of Private to remind on Securities Reform the call harbor making forward-looking caution that listeners will be I statements. management could to associated results statements business. or from implied by stated Actual differ those risks materially our forward-looking with due uncertainties and the These forward-looking are in filings. today's in their their entirety statements statements contained cautionary SEC qualified release and press by date call time-sensitive February accurate this broadcast, that of XX, XXXX. conference content The contains this of live of information the is only as no obligation of the after statements or or update and revise date events reflect to webcast. any to We forward-looking circumstances this call conference undertake

and a detailing and this the recorded webcast Investors www.esperion.com conference being a within of content and be the release As press copy found today's call. at section. call reminder, can are A issued this Media We archived. afternoon

We for with your the will open call questions. prepared comments and begin then

to available speak like call, Mayleben. will today's team President CEO, e-mail minutes our the and call follow-up turn with Tim to Tim? XX be the Please questions. investorrelations@esperion.com our Following team. now schedule to for I'd over to

Timothy Mayleben

update as keep Since brief results believe and financial Ben, on we prepared we ago, we today you, good and Q&A. Thank get you weeks into we'll preliminary us the appreciate afternoon, several announced We ahead. and opportunity remarks joining Esperion, everyone. lies still that our significant you

be everything the we'll year changed. as Now for many, XXXX remembered

an acid, Esperion as bempedoic us combination NEXLIZET, This team received world realize, and XX and accomplishment tablet fixed-dose and in company. bempedoic of commercial that moving the marketing never us approvals to an obvious While We and the R&D around making partner. company for ezetimibe, global our years ever changed in and first changed in NEXLETOL, fundamentally nonfat did. R&D was organization one more ways, our first companies acid from a the an most than

additional and brand worked while EU collaboration We to launch Sankyo QX, We approvals with Europe, the strategic with under NILEMDO commercial commercialize medicines names our Japan. secured marketing in U.K. in Germany the Pharmaceutical NUSTENDI. partner, Switzerland a our and earlier also Daiichi Europe, Otsuka develop and to in announcing in

safely vast rest impacts the All people of of the stayed and the majority against battled this, as at world and COVID-XX, of home. we the uneven of

NEXLIZET NEXLETOL future statins, the But in time prescriptions U.S. filled tolerated for and to which the medicines achieved statin long-term by metric levels in statin care in Following of feedback we non-statin in commercial this, is diet important launched the while NEXLIZET despite confident year their cholesterol This positive the written we in and fewer that before. we XX,XXX than And second approvals how patients to opportunity and hear working of the haven't history in year-over-year. NEXLETOL and XXXX, combination their our FDA, health prescriptions the avoidance medicines, our resoundingly was patients patients' yet we resulting about our are to for remains the in fewer quarter for potential providers continue prescriptions with prescriptions in XXXX the intact. U.S. maximally lower first ventured an Throughout LDL-cholesterol far are success. virus, bad declined lowering XXXX.

take discover, options. innovative that are management company, get, We constantly easy easy seeking experiences, and are medicines those to patients' lipid we and work commercialize with in to to current being established better especially develop easy to combinations by met to have. understand the whose medicines aren't treatment As needs

goals our designed upon CLEAR delivering levels intolerant we won't and CVOT that team. the patients people of intolerant hsCRP high record track positive pandemic, aim patients outcomes non-statin impressive death additional quo. a the successfully first cardiovascular enviable for for statins, as medicine its our team unmet XX,XXX of in on and call to statin enrolled, individuals in result, the or attacks patients with trial, the to patient success that over in cardiovascular who CLEAR group about now heard trial, cholesterol-lowering impacts to development of a cardiovascular XX% that commitments a of up than effects. options. pills to than tolerated the statin completing in We've the oral there focused The showing the for CVOT, outcomes intolerant need non-statin, landmark ability beyond in LDL-cholesterol fully And statins, you and and because change intolerance the event-driven on like new R&D the world-class statin affordable. the statins. are cardiovascular non-statin a for is reach better in pioneering potential determine need cholesterol EU. and disease. a status the of an can't focusing what the many the This literally overall is majority population have Despite world potential development landscape, who Statin invested XX of events, who, underinvestment track. In particular, it a an demonstrate their therapies acid, are maximally drugs leading convenient, We is that is tremendous have We full vast once-daily a is in cause cardiovascular statin of been remains reduce statin of world. #X adults heart levels risk more landscape CVOT to reduce tens strokes. events as in around for significant We bad has in believe bempedoic that resulted among risk need maximally such the acid additional therapeutic times considered lower the can't tolerated of need a million reduction the There at U.S., the with us there is of will are with bempedoic powered glycemic on the past. take have treated lowering millions kind, speak patients LDL-cholesterol of patients. of the With is diet Japan and and their optimally deserve

Daiichi to for major again, to, of prove next that In patient we CVOT the half quarter been XX% deliver for the fact, year. other cardiovascular field. second in entered our promise by on X,XXX around challenges on of the of Positive Otsuka upon willingness also the In our on within in the the leadership hard of the and purpose-driven Germany which first with underserved. We're alone, collected third working the patients X results primary We've groups endpoints both were and collaborations the companies once the with world. cardiac DSC. in during into adverse Europe target potential and XXXX, Sankyo remain Japan, from have will take launch have have to medicines events, our extensive the of our experience months

fact, study initiate a plans this Otsuka QX, in in II to Japan, quarter. Phase For

company the further completing network, exclusive the that last of continue trust cholesterol. world around patients medicines even bad with XXXX, We're grateful be opportunities forward bempedoic patients remembered pandemic work reach optimism. support rights high our the of levels pride will our world increase and in our to with value. our the leaps great partnership, as to bempedoic medicines. world. XX% thank own of of We rest of the and place accomplishments the major the acid piece care for almost shareholders world post for a the their Perhaps your of year struggling will everything future acid patients In rest through still look and health in We global will to and forward completing the to changed, our global of most Esperion who we after including to importantly, providers ongoing closing, Esperion, franchise partnership take

Next, with is ability in as our remains recedes. extensive especially expense Officer, strong will streams, us how a on I'll he to position. and it Bartram, to focus our Chief are applying Rick that, grow pandemic conservative medicines bring to how maintaining to the as cash the a CFO, with our share what Operating pandemic, With Sheldon, joined management, reinforcing will recently position leadership our his who experience highlight cardiovascular Then the turn company's Sheldon. we during of diversified revenue us Sheldon?

Sheldon Koenig

everyone. Thanks, good Tim, and afternoon,

of background and you, I highlight like me had For to brought yet, Esperion. what all pleasure to my meet a to give I'd of haven't brief the

U.S. From and until of I from a first marketing Over of our few organization global long up to Officer managing decades, franchise I these obtaining offer. on and in accelerate to Most experience and served Portola, with the space in took NEXLETOL roles been the Merck, have Zetia LDL-C marketing commercial as the within medicine the is across and the realized XX patients. there, the the today. global all recognized has lead at operations lowering access moved to business for ground market and from cardiovascular in years recently, potential and cardiovascular extensive global time sales, Regeneron. building of solutions of adoption worked worked Praluent franchise global launches space. Sanofi of I've I've worked my run learnings the commercial In Commercial U.S. plan overseeing their NEXLIZET path very apply cardiovascular I to and I CV to really relationship business, the the market the cardiovascular the U.S. full I and ensure Chief the in directly and including the VytorIn. spent directly and various with for last short,

risk additional options LDL-cholesterol XX as patients goal. concerns with cholesterol, combination marketed Within current these to once or part reach not I apparently that to call here ezetimibe made needed Esperion their injectable now the cancer X the that my X solution, And of this is the worse because daily with battle lowering to was that Bempedoic million are acid to oral dying tolerability a to comment wake-up staggering LDL-C the in be support every NEXLETOL the once your their need. battle people than meeting biomarker always deaths. a leading U.S., in my are solutions about is and there's treatment killer. the need On NEXLIZET world's patients accountable said, and what's necessary about "Be after worried the the PCSKX joined is This from killer, managing They of cardiologist. either cancer." I a enough KOL as more due #X non-statin statins inhibitors disease, silent millions he the gap estimated worried for tolerated personal easily more between a medicines. I disease asymptomatic, of of to visit therapy cancer, delivering and the elevated patients maximally cardiovascular CV to note, fill known with diet, U.S. returning, because want a lead I for

As I and was high-risk soon I a history. of learned, LDL-C baseline XXX level a milligrams family per deciliter with at

at usual NEXLETOL their and a the forgoing to standard medical result the other this before me lifestyle when ever. pandemic, people not launch all opportunity us. medicines is healthy managing important as did LDL-C is than are afforded checkups now of to So and more NEXLIZET get time active It clear LDL-C

from to make an have we as pandemic. accelerated all do we emerge an opportunity impact However, this

is physicians' Esperion environment, if, and a implementing commercial customer-facing we will and of to cannot when. momentum garner patients the ensure increased they matter are awareness identified certain medicines. the of who changes was I've untapped to discuss that offices which experience, to refined MSLs influence in as pandemic leverage. a the sustainable on arrival a move that, X as a number NEXLETOL strong a of science medicines lowering best medical such MSLs and interim, the amplify franchise. of strategy, gap of developing Driving NEXLIZET of they I date, and to specific align community the In can the therapies. medical LDL-C are first of there in Based additional will building or to with our One week the of patients of positioned and initiatives, education month, medicines new respective instrumental we diverted hyperfocus scientific to-do groups but efforts. I've is return business. health collaboration need liaisons integrating our to to communications KOLs relationships half for across is also look easing synergies medicines in Since moment, significant in capture the Although also with my patients has receding, will the the it. in for you my pandemic. provide potential again with droves. during to a but in and return care It not we the large while platform, areas awareness adoption professional an we'll our educating offices increased the benefits pandemic, with scientific are broader the of through for will better is adoption medical this be growth long-term largely abate, my been number wake this once Physician But in prioritized. attention now initiated better physicians' internal Esperion, of organizational give

and with are As granted team of for power treatment to this corroborate depicts franchise the lowering Clear the the the Not LDL-C will physicians real NEXLETOL monumental with the Tim should mission, exist exposes that hundreds evidence out, our treatment hands to that deliver of allow to and our expansion. be until we the of Esperion put a medicines. experience study firsthand therapies touched outcomes will innovative indication But also products a even this commercial today. earlier, of study directly on shortcomings will the be we current marketed well paradigm trial looking them in currently but manner, reads that the the only our

been coverage. effective, proposition. overwhelmingly value lost and of and ability economics to physicians our believe enough longer-term medicine. not look health our around our our not physician is area focus all coverage support and and and our point decision-makers outcomes will into they to alike. to patient treatment have relevant We our it regarding taking only lives. since continued guide Part will medicines, our fit. growth. their clinical product way, translate encourage to number last experience development of by critical D with intend products payers specialists the pocket economics meetings in use majority preferred care health drive We We'll publications and target improvements is care of The I on physician will are and continue along this create on which given with just demonstrated I'll brand build, host prescription increased further motivation vast feedback educational peer-to-peer the day. ensure will were and to We especially that acceptance virtual positive working and managed that team was essentially broader precision This a but market products, confident we But of favorable messaging a care even It Medicare health patient virtuous to of paradigm, covered our to tiers are providers access reinforcing more encourage on the HCPs work this out our population we create are the this medicines leverage our cycle continue we patients' cost-efficient where products managed has that behind patients. for our new costs, research action results, with and whereas is to are are the The a on the patient onboarding physicians understand lowest of managed know care, to that appropriate of our complement facilitating our turn enhanced to pull-through commercial positioning in greater medicines use HCP. The to

such Part managers bridge potential demonstrate Cumulatively, we into to once hasten throughout, the online, confident emerge and the are joined this especially NEXLETOL to NEXLIZET, of initiatives we our cost, marketing contract a constrained and addition as account hold team's have building not implementation. D from Esperion come environment. long-term updates time no What We believe am last through With access felt if non-statin our providing of dividends the oral, and are We means additional reimbursement leading pay will demand gap effectiveness hand to on to I'll integrating access in little the advancement completion side, will responsibilities additional volumes. ability on you to I hire Medicare this medicines execute. and improved some as to turn I our prescription implementation. strategy now and we coverage to performance. and with take each progress forward months to medicine specialty and of for would to differently. to to the market commercial this on are now daily, I that, efforts call contract remarks for implementing will this in over to in the I bit cultivate of look for between our the our the come. full requiring our which financial the Rick is these

Richard Bartram

the my Sheldon. steps in revenues required COVID an I'd Today, create our model structure Thanks, to conventional more disrupted a taken Esperion normal By now, all time interrupted health management launch, commercial U.S. has COVID and we order addressing with like I'm optimization our impact associated to care sure plans of a on the how how and you're product spend aware, cost business what practices. sustainable future. our for model have and health

example, refills. for we overnight, the launch lab tests stopped depending regular prescription office its commercial a tracks. environment in and successful physician on For U.S. were visits, Seemingly,

opportunities several necessary our R&D a and late-stage initiated first building into and we an our company of revenue $XX year the XXXX R&D the processes identify our million fought and efforts For all cost evaluation On business, of hard support savings, function from on the being U.S. to commercial the the million. for a expenses transformation revenue in and implement roughly for inventory. revenues significant adaptations commercial with we $XXX.X million, $XXX organization, of commercial out side and to after product of and generated total full collaboration systems

wholesalers demand, our cautiously adjusted year, associated negatively As managing in we and of savings. our production budgeted result plans last COVID a inventories, more resulting impacting

As market for initiatives our we investment. a on high-return focused pre-COVID marketing budget and original revenue with conditions of ramp, these subsequently on rightsizing ROI threshold internal assumptions was activities based prioritizing and normal on

the to there cost. make explained had the teams come NEXLIZET the Sheldon the conducted well for performance number we initiatives where as earlier, and our and additional year throughout to the that support was non-sales that reviews, to U.S. Overall, potential In This commercial little place environment team As decisions growth and also The no launch. field on with for shelter customer-facing standard of supported includes NEXLETOL are a to other in. that footprint, and the difficult hotspots functions of commercialization as the force, COVID also adjusted workforce company geographies near-term management sales we're modified current notices. that adapt

guidance guided down reflects included commercial the but Our this expected XXXX prudent inclusive OpEx to decline February with Since annualized $XXX this slightly expected cost To XXXX represents guidance $XXX our savings expense, original the state X well original expenses from culminated R&D OpEx is last $XXX enrolled full study. to noncash expense. CVOT falling of XXXX costs total associated below compensation the of of steady year, full million, year of million review, range for Furthermore, million. million generally, an the months fully between $XXX year of approximately only be million million $XXX of expense XX%. month, operating expense $XX $XXX we stock operating XXXX in million, activities expenses last management XXXX to of approximately $XXX full year for to million,

cash year is million ended million million. in full in to $XXX SG&A expense XXXX the of with We approximately range anticipated Our hand. XXXX on $XXX $XXX

will to based receive this world bring additional million revenue further additional Oberland will remain we an balance addition, from $XX of rest confident additional year. cash a agreement cash payment upfront us will provide sheet. near-term deal, our funding with Both an Capital In existing our we

collaborations. $X and execute, management initiatives revenue-generating the cost our like sheet Overall, to CVOT over I partners continue months to all to would with our on remind preservation our study years should are that ex-U.S. monetize to or Finally, balance future feed billion continue first-in-class payments in on you and focused we in as ahead high-return milestone Esperion our our the investment. initiatives will has existing from decide these. of These

reinvest are right organization, nimble We the that a time structure and environment more allows an us now with cost approves. as external is the when to efficient

assess forward, turn advance resourced cash we that, With business greater to the against it continue create the shareholder potential value. the and remarks. to Going will growth Tim for I and spend organization adequately our closing ensure back will to is

Timothy Mayleben

close an to you, Thank throughout COVID-XX The Rick. that faced day. XXXX obstacle to like unforeseeable pandemic all and I we with this would just this. was

However, us think potential forever. prepare negative into through headwind. challenges of that the confident partners for to return growth medicines. the in continue really patients won't We look very for a the our fight coming to as and Esperion impacts short-term and we'll COVID-XX future to our COVID-XX long-term Both to our is the a We is need ability the be the and forward And months of to hands our them. for get with remain bright accelerate Esperion, medicines. the the of we therapies normal

want joining poll for I you please to questions. So Operator, for call. today's thank

Operator

[Operator Instructions]. Suisse. Martin our the first Auster And with from line Crédit coming of question

Mark Connolly

on Mark for is Marty. This

So on there were Tim, that I had in Germany -- that mentioned you patients I that my is, you bempedoic I X,XXX question saw thought guess first had acid.

yes, to pace additional extended the any And these details in launch guess, to any you of that the provide? I able perspective were you help access put so would relative programs? And the in And patients could of U.S.? in be X,XXX

Timothy Mayleben

Mark, this Sure, Yes. is Tim.

years is, think, number. an provided accounts, two the that almost with made number. to partner we the we Daiichi It I decision So Sankyo. cements really impressive ago It all by

incredibly successful and the an Europe, people numbering commercial phenomenally said ago. than you'll several they time As cardiovascular of we the across launch launch remember, had LIXIANA they more the that with and been years had X,XXX at organization, have successful

well So expected perform extraordinarily there. we they certainly to expected --

early commercial the the to Our numbers I numbers, understanding their you strength is playbook, early of running organization. LIXIANA. indicate they're a launch And will, these patient of think very if similar

paying can of. not, these are think we're -- commercial these is patients, that patient way, what assistance that patients, not true aware any we are programs in I say

an it's I think Europe, said, the of early numbers. think indication the Daiichi Sankyo. of but and early, certainly I in indication, it's good So organization it's an But early I like capabilities

Mark Connolly

It I'm to worth if second or question keeping my size agree. of get curious the agreement? is, any been update I And discussions I we just Yes, going? an on be track update should then how just thinking terms potential timing there's about be will of. definitely rest-of-world partnership have And guess, in how of that potential

Timothy Mayleben

Yes, Yes. Mark. sure,

So good question.

said So It's we is the and for think the of as to we earlier We in to rest quarter. our remarks the world. about optimize our good obviously, last I goal year, this tracking ascribed value remains completion that prepared feel -- year late that. said in

towards we're we that again, timing. so -- And tracking

Operator

BTIG. coming of line Your next question Shrader the with from Tom

Julian Harrison

This Julian on the quarter. for Congrats is Tom. on

U.S. prevailing then, trends could lipid And an maybe also the among center launch, revenue specialists Regarding I'm U.S. regional to uptake? any as GPs? versus wondering comment geographic versus for gross net. improving if Rick, such script you implies And growth community XQ on

this to are the here? long? And that for you So factors remind maybe so, should I'm if if expect continue? us wondering what approximately we And can play how trend

Timothy Mayleben

others? Sheldon, then to tip take can Rick to the the questions you I ask respond and to first to it

Sheldon Koenig

And much. so for Thank Yes, we'll do. you the question. thanks

X% a showed by this of back. the we're statins use had where it in JPMorgan, still that, HMG to So see We about that statin as currently. decreased. But seeing rise prescribing, you overall is decrease may come slowly and we relates we seeing are what prescribing, recall

versus As Obviously, more it PCPs prescribers both. relates by more of essentially are think PCPs, than there's I so there cardiologists to the cardiologists. it's contribution

physicians, see that type with isn't slightly you also and disparity. and see primary do And more you prescriptions geographic really care So cardiologists, any from There growing. growing. of

geography back which states I all deeper the it vaccine, from job a that just think to, it some seeing has coming from back of for others, news out relates treatment, physicians patients are coming bit better we relates if some watching but as I states do some back think coming some as to any are rolling patients a stated we're than doing know, have the slowed, even patients a slower, the really we and disparity slower question is COVID quicker. not perspective

done just Now a our we That's an of -- at not basis. the receive on that. that in -- some overall intense we some have research data weekly of looking

Timothy Mayleben

Rick? Sheldon. Thanks,

Richard Bartram

Julian. Thanks, Sure. Yes.

So know, we purposes. for we've disclose gross as pretty nets don't our been competitive to that consistent you really

As at. think we our nets, Sheldon coming gross are as in continued particularly online, to pleased going overall, space. the Part level have But we're we're to D as come pleased start ahead things obviously, the about currently have proceed in we're online. volumes, at. out nets all where And gross to will in we with remarks, where prepared And to plants plans and mentioned increases as

Operator

Yee with Our next of Jefferies. question coming from Michael line the

Michael Yee

volumes up medicines. talk about Do February types are of things in maybe January, our hear different Two of We side. feel you doctors seeing in you're the patient and the what different the picking time like questions frame, just from different on environment? types

see if think issue quarter. about maybe good you the So you you sequential is sequential relates do an that. a just $X.X million number your going fourth is pickup I that to to a in should growth? confident And acceleration, about which feel a confidence make $X COVID as did comment million, in

talk alleviates ramp things? to So follow-up. those I X do about see COVID of have kind as a then you that And

Timothy Mayleben

Yes.

Okay. Great. I those you? to Sheldon, can tip

Sheldon Koenig

will do. thank question. your for you, Michael, And Yes,

occur. month I any back, field. that return seeing that place We speak that think that that data normal. And currently to think waiting for we're if will that, anything, frame deadliest more the we're rollout really still that, is we But physicians return once time will just expect we return have we'll over back, capture see them essentially vaccination and do as We're what we're themselves that growth all And up accelerate. don't we be as trickle patients taught Just quickly specific went it's we as actually was we coming with when monitor offices to flexible from not that. have really are more you But as this office And the well and of But to a normal situation. what is I to as January to to COVID. the has XXXX slow the to it -- see coming in is can opening initiatives mark, patients. unfortunately. XXX,XXX know, death patients related back. we necessarily patients we the quantitative vaccinated, to how we'll on a it to giving will relates working the it's see get really our information us

Michael Yee

if I patient on But each the or month, have Should general, think just you quarter in on. to have are steady think because commercial should volumes in should right way people should about should staying better, more each people quarter? work it accelerate or your each coming sequentially that you getting be you guess, acceleration

Sheldon Koenig

each work getting offices. medicine. vaccinated, our will forward are, that patients resume vaccinated, mean offices, is hope One and move that As patients I physicals. they is we quarter themselves physicians, their that thing patients going with learned are Telehealth in truly were cardiovascular doesn't more really not as to more I yes. think, we've

that shows research have even patients and getting weren't panels. lipid their therefore, that, We

a we and upon as acceleration matter growth. quickly pandemic. hope that, of as of timing It's out this just we a cases continue number offices, based initiatives of it as default, return our to are doing, that putting initiatives we et by and cetera. to relates in think, will emerge I to vaccinations, from that upon point, all of all the to patients based see mean we're declining, in I how we see would our we're place, perspective, So physicians' that what your marketing

So people now to comfortable and their just physician. matter vaccinations of it's more a feeling going

Michael Yee

good Do That's those work? And them had last Yes. slide in packs to Maybe there starter Can any just transition on me people they -- just how big us number work. a for and you commercial? deck. just then Do remind to packs. you a how Can 'XX. you comments remind starter for related the your while? question stay

Timothy Mayleben

Sheldon? Yes,

Sheldon Koenig

Yes. Sure.

samples. our distribution essentially physicians It's And really of audience. target are packs and our all starter are samples. So it's samples -- distributed essentially to

the bit at the then And of typically so it configuration, a days. We go usually the drug the sample with a prescription, local have the box prescription try X-day and the physician quite there, it's for the the samples can on they sample pharmacy. from given fill and patient they're X and patient to a ahead distributed allows And then take drug.

Operator

Our Meacham next America. from Geoff of of line with question the Bank coming

Olivia Brayer

are more of that, through external whether going years? other strategies? at aggressive development becoming to to Brayer. Tim, should better I'm follow-up forward. more get BD a or partnerships diversification that's is as I whether then and wanted that driving we capable guess to ask next focusing more a an And Or for a to a point, the this pipeline stage on priority mainly going forward, expect do sense trying Olivia point, approach for is at programs? is you within there mid-stage earlier maybe BD growth few is This of on I appetite deals this it

Timothy Mayleben

that success say, cardiovascular CLEAR which, progressing in I the the environment. is two, think, brief you heard is have broader NEXLETOL for you on extraordinarily of well, of XXX% is, study, the study a answer Olivia. outcome one, success and as organization, X Rick outcome heard COVID Thanks, say, will I the as NEXLIZET; you, and and things: especially very us the focused this commercial which study,

this drivers. So said, like focused organization X is nothing at entirely on more Really, say business to point those development. this on I

Operator

Chad the coming of Company. question with & line next our Messer And from Needham

Chad Messer

Congrats on progress. solid some

it's OpEx in look with the Just a environment. to great XXXX taking ship, tight especially and guidance, run uncertainty a at your

comp environment. have optionality Just the and more like and favorable yourself a in do think enough have very in a you've to XXXX, pursue and you that narrow tight you case. things a to range wondering favorable It upside baseline If we downside pretty a seems an got obviously, granted with -- window. all

warranted? whether you Just enough the situation comment could on you be wondering on you can whether if feel aggressive

Timothy Mayleben

to you comment? do Thanks, Sheldon, Chad. Yes. want

Sheldon Koenig

Yes. Sure.

our I So we necessarily very equipped forward to think team, in to and line also growth again, which will things to are based do. equipped initiatives with we These products, in we -- platform today liaisons some give, need that putting things but be strategy our medical of that that And able the in for better mentioned side the we've do to lack accelerate essentially I are to are science doing that in thinking and I of that move sight think where affair our in well greater medical comments the we're think, building. that and changes of on we commercial are being prepared place, These and not XXXX. we our positioning and I our not scientific of time. words, only purposeful are be what will really upon the organizational cost of money. made, just take the that

Operator

next line Joseph from question of the our Thome with And Cowen. coming

Joseph Thome

did specific on kind thus sort the treatment that do patient and is appropriate second, to compliance, clouding faster? assets where of part you specific lost? is back COVID then terms of to to and just isn't emphasize come forward that mostly tend paradigm there stay kind real-world Or of in of a kind NEXLIZET product? sort getting think interactions? get once going coming is fit. of on you they it on, that and going refills Or there Is patients population message in on patient and is surprised of along far Sheldon, come do educating And of the physicians population use be you will are the a NEXLETOL

Sheldon Koenig

yes? Tim, Oh, Yes. Craig. Yes. Yes,

So that. apologize for

looking patients, messaging as some we actually et work right So it now, segmentation. at patient is and which cetera, to ongoing specifically relates have

to along that COVID And company a we as and to months due platform into with the also the that that. the why scientific point, forth, scientific set we was we of few patient the one so that during to and our and And go the population your messages reestablish unmet up to fact it to somewhat next and goes that to this launched need with relates bit back things you that. COVID as define appropriate go think our awareness that lost. was the issues have, the I we'll need definitely cloudy really update

if just repeat give you your question? was, me could question second -- Your second

Joseph Thome

real-world and refill. on compliance Yes,

Sheldon Koenig

refill. on Yes,

that what we've refilling are benchmarked we've ourselves seen, have the looked patients used. actually prescriptions, majority products actually see we compliance, we at are sign. and real-world to So good their commonly And a refills, of other which is

Operator

from So the line with coming our is issues. Derek technical His Stifel. line with of coming next in Archila

next with line from Choi Paul Sachs. coming the Goldman question of Our

Unidentified Analyst

that's quarter's Two on then year? is year the just -- okay. was me, the for question regarding Paul. launch for inventory assistance for there ones my we're plans whether wondering influence any if was throughout I is sustaining as And quick co-pay This this or throughout Charlie are wondering if XXXX, second is in there improve hoping not numbers. to the in patient

Timothy Mayleben

tip Yes. Rick, can to that you? I

Richard Bartram

Yes.

the no program is us. obviously inventory that, revenue. So something intact and terms those, co-pay that's short that but on to impact We're evaluate of 'XX to is continue going to for important in on answer,

Operator

Thank all participating. today's conference no And questions at for I'm further call. you time. concludes This showing this

disconnect. all may You

Timothy Mayleben

Thank much. you. so you Thank

Esperion Therapeutics (ESPR) 24 Feb 212020 Q4 Earnings call transcript